Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00771875 · ClinicalTrials.gov registry record · Phase 2
Randomized Trial for Mixed Acute Rejection
A Phase 2 study, sponsored by University of Cincinnati.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT00771875: Completed Phase 2 study, sponsored by University of Cincinnati.
NCT00771875 is a Phase 2 study that has completed, run by University of Cincinnati. The registered enrollment target is 30 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (77% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00771875, a Phase 2 study, has completed, sponsored by University of Cincinnati.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
This study is being conducted to determine how safe and effective using an immune cell (b cell) depleting therapy and/or Thymoglobulin is in patients with a kidney transplant who are experiencing certain types of rejection.
Primary Outcome
Rejection Reversal is a return of serum creatinine to within 115% of the baseline value, or histologic reversal occurring within 14 days of initiation of treatment. Recurrent Rejection is histologic evidence of rejection noted on a biopsy specimen obtained up to 3 months after documented rejection reversal.
Interventions
- DRUG Acetaminophen
- DRUG Rituximab
- DRUG Bortezomib
- DRUG Antihistamine
- DRUG Rabbit Antithymocyte Globulin (RATG)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2008-09 |
| Est. Completion | 2013-03 |
| Phase | Phase 2 |
What the finished NCT00771875 record still lists
NCT00771875 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (77% lower).
The record links to 0 conditions, and to 5 interventions - of which Acetaminophen is the first listed.
NCT00771875 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00771875 about?
NCT00771875 is a clinical study titled "Randomized Trial for Mixed Acute Rejection". This study is being conducted to determine how safe and effective using an immune cell (b cell) depleting therapy and/or Thymoglobulin is in patients with a kidney transplant who are experiencing certain types of rejection.
What is the current status of trial NCT00771875?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2008-09. Estimated completion is 2013-03.
What interventions are being tested in trial NCT00771875?
The interventions under investigation include: Acetaminophen (DRUG), Rituximab (DRUG), Bortezomib (DRUG), Antihistamine (DRUG), Rabbit Antithymocyte Globulin (RATG) (DRUG).
Who is sponsoring clinical trial NCT00771875?
This trial is sponsored by University of Cincinnati, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00771875's enrollment target sits among peer trials
30 1582nd of 2000 higher than 332 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia